CHICAGO, July 28,
2024 /PRNewswire/ -- At ADLM 2024 (formerly the AACC
Annual Scientific Meeting & Clinical Lab Expo) in Chicago, more than 300 experts will present
cutting-edge research and technology that will shape the future of
laboratory medicine and improve patient care. From July 28-August 1, the meeting's 250-plus sessions
will delve into a variety of timely topics, including the health
consequences of ending federal protection for abortion in the U.S.,
a recent Food and Drug Administration (FDA) ruling that could
significantly impede patient access to essential laboratory
developed tests, and how to harness data science to achieve health
equity.
The case for clinical trials of lab tests. Clinical
trials are the recognized standard for evaluating pharmaceuticals
and other clinical interventions. In the meeting's opening plenary,
Dr. Patrick M. Bossuyt will make a
compelling, research-based argument for why clinical trials of
laboratory tests should also be used to support practice
guidelines, reimbursement decisions, and more. Dr. Bossuyt is the
recipient of the 2024 Wallace H. Coulter Lectureship Award and a
professor of clinical epidemiology at the University of
Amsterdam.
Lymphoma biomarkers and therapeutic targets from mass
spectrometry-driven proteomics. Dr. Kojo S.J.
Elenitoba-Johnson, chair of the department of pathology and
laboratory medicine at Memorial Sloan Kettering Cancer Center, will
deliver a plenary about the emergence of mass spectrometry as a way
to assess complex protein mixtures in patient tissue samples, a
technique that allows clinicians to detect cancer and develop more
targeted treatments.
Pharmacogenetic testing in precision health. In this
plenary, Dr. Ron H.N. van Schaik,
professor of pharmacogenetics at Erasmus
University Medical Center, will explain how pharmacogenetics
uses people's unique genetic profiles to develop personalized
therapies for diseases. He'll describe recent challenges and
successes in this field that could benefit patients in psychiatry,
cardiology, and oncology, along with pharmacogenetic-testing
developments that will further refine treatments.
Providing more options in HIV prevention. Current
HIV-prevention medications have limitations. Oral antiretrovirals
combining tenofovir and emtricitabine reduce HIV only in certain
people, while an injectable form of cabotegravir is effective but
expensive. In this plenary, Dr. Sharon L.
Hillier, director of reproductive infectious disease
research at Magee-Womens Research Institute, will discuss the
development of new prevention options for at-risk populations.
Projected consequences of ending abortion protection. In
this plenary, Dr. Diana Greene
Foster, professor of obstetrics, gynecology, and
reproductive sciences at the University of
California, San Francisco, will discuss the changing
landscape of abortion law and its impact on patient care. Drawing
on data from nearly 1,000 pregnant people at 30 U.S. abortion
facilities, she'll describe the health and socioeconomic
consequences of receiving abortions versus carrying pregnancies to
term.
Special session on laboratory developed tests. This year,
the FDA released a final rule placing laboratory developed tests
under FDA oversight, even though these tests are already regulated
by the Centers for Medicare & Medicaid Services. In this
July 30 session, representatives from
ADLM, the American Medical Association, and the Children's Hospital
Association will discuss the negative impact this rule will have on
patient care. They will be joined by a caregiver and patient
advocate who will give the patient perspective on why laboratory
developed tests are so important to timely diagnoses and
treatment.
The winning entry of the FairLabs Data Analytics
Challenge. The University of
Washington Department of Laboratory Medicine & Pathology
Team has been named winner of a competition challenging
participants to develop analytic tools that promote fairness in
peripartum urine drug screening. ADLM 2024 attendees can learn
about the winning entry and how to apply data science to health
equity at the Health Equity & Access Division breakfast meeting
on July 29.
"From plenaries highlighting testing breakthroughs to a
session on achieving health equity through data science, to a
critical discussion of the FDA's laboratory developed tests ruling,
ADLM 2024 showcases how clinical laboratory professionals are
making bold moves every day to advance medicine around the globe,"
said ADLM CEO Mark J. Golden.
Session information
ADLM 2024 registration is free for members of the media.
Reporters can register online here:
https://xpressreg.net/register/adlm0824/media/landing.asp
Plenary sessions
Session 11001 Why we need more strong clinical trials of
laboratory tests
Sunday, July 28
5-6:30 p.m. U.S. Central Time
Session 12001 Lymphoma biomarkers and therapeutic targets
from mass spectrometry-driven proteomics
Monday, July 29
8:45-10 a.m. U.S. Central Time
Session 13001 Implementation of PGx-based testing in
precision health: Do you have your DNA-passport?
Tuesday, July 30
8:45-10 a.m. U.S. Central Time
Session 14001 Empowering choice by providing more options in
HIV prevention
Wednesday, July 31
8:45-10 a.m. U.S. Central Time
Session 15001 Projected health and social consequences of
ending the federal protection for abortion in the United States
Thursday, August 1
8:45-10 a.m. U.S. Central Time
All plenary sessions will take place in Room S100 of the
McCormick Place Convention Center in Chicago.
Special session on laboratory developed tests
Session 13002 How FDA oversight of LDTs will affect patient
care
Tuesday, July 30
4:30-6 p.m. U.S. Central Time
Room S100, McCormick Place Convention Center
Presentation of the FairLabs Data Analytics Challenge winning
entry
Health Equity and Access Division and the Data Analytics in
Laboratory Medicine Committee breakfast meeting
Monday, July 29
7:30-9 a.m. U.S. Central Time
Great Lakes Ballroom A, Marriott Marquis Chicago
About ADLM 2024
ADLM 2024 (formerly the AACC Annual Scientific Meeting &
Clinical Lab Expo) offers 5 days packed with opportunities to learn
about exciting science from July 28-August
1 in Chicago. Plenary
sessions will explore the projected consequences of ending abortion
protection, new HIV prevention options, lymphoma biomarkers and
therapeutic targets, pharmacogenetic testing in precision health,
and the need for clinical trials of laboratory tests.
At the ADLM 2024 Clinical Lab Expo, more than 900 exhibitors
will fill the show floor of the McCormick Place Convention Center
in Chicago, with displays of the
latest diagnostic technology, including but not limited to
artificial intelligence, point-of-care, and automation.
About the Association for Diagnostics & Laboratory
Medicine (ADLM)
Dedicated to achieving better health through laboratory
medicine, ADLM (formerly AACC) brings together more than 70,000
clinical laboratory professionals, physicians, research scientists,
and business leaders from around the world focused on clinical
chemistry, molecular diagnostics, mass spectrometry, translational
medicine, lab management, and other areas of progressing laboratory
science. Since 1948, ADLM has worked to advance the common
interests of the field, providing programs that advance scientific
collaboration, knowledge, expertise, and innovation. For more
information, visit www.myadlm.org.
Christine DeLong
ADLM
Associate Director, Communications & PR
(p) 202.835.8722
cdelong@myadlm.org
Molly Polen
ADLM
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
mpolen@myadlm.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-consequences-of-ending-abortion-protection-the-patient-perspective-on-laboratory-developed-tests-health-equity-and-more-to-be-explored-at-adlm-2024-302207915.html
SOURCE Association for Diagnostics & Laboratory Medicine
(ADLM)